Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03935347
Title Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Roswell Park Cancer Institute
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Roswell Park Cancer Institute Buffalo New York 14263-0001 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field